비교리스트

 카트 문의
시장보고서
상품코드
1388792

세계의 중증근무력증(MG) 치료제 시장 : 약물 유형별, 연령대별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 및 예측(2023-2030년)

Myasthenia Gravis Treatment Market, By Drug Class, By Age Group, By Distribution Channel, By Country, and By Region -Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 303 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서의 주요 내용

중증근무력증(MG) 치료제 시장 규모는 2022년 20억 1,243만 달러로 평가되었고, 2023년부터 2030년까지 연평균 복합 성장률(CAGR) 9.4%로 확대될 전망

중증근무력증(MG)은 머리, 안구, 사지, 척수, 호흡근의 근력 저하를 유발하는 만성적이고 희귀한 진행성 신경근육질환입니다. 이 자가면역질환은 아세틸콜린 수용체(AcchR)에 대한 항체가 생성되어 신경에서 근육으로의 적절한 전기적 신호 전달을 방해합니다. 안면신경마비, 눈꺼풀 처짐, 복시, 보행 장애 등이 중증근무력증(MG)의 증상입니다. 이 질환은 항체 혈액검사, 자기공명영상(MRI), 에드로호늄 검사, 반복신경자극검사, 컴퓨터단층촬영(CT) 등 다양한 검사를 통해 진단할 수 있습니다.

중증근무력증(MG) 치료제 시장 - 시장 역학

중증근무력증(MG)의 세계 유병률 증가와 인지도 상승이 시장 성장을 견인하고 있습니다.

중증근무력증(MG)의 세계 발병률 증가, 중증근무력증(MG)의 혁신적인 치료법 채택, 조기 진단에 대한 지식 증가는 중증근무력증(MG) 치료 시장의 발전을 촉진하는 주요 요인입니다. 또한, 제약회사들이 질병 치료를 위한 신약 개발에 집중하면서 중증근무력증(MG) 치료제 시장은 괄목할 만한 성장세를 보이고 있습니다. 또한, 면역억제제 및 단클론 항체를 포함한 다양한 약물이 중증근무력증(MG) 치료에 대한 효능을 시험 및 개발되고 있습니다. 그러나 중증근무력증(MG) 치료에 사용되는 약물과 관련된 부작용이 조만간 시장 성장을 억제할 것으로 예상됩니다. 또한, 의료 전문가와 환자들 사이에서 중증근무력증(MG)에 대한 인식이 높아지면서 효과적인 치료법에 대한 수요 증가에 크게 기여하고 있습니다. 이에 따라 더 많은 사람들이 중증근무력증(MG)의 증상과 위험에 대한 인식이 높아짐에 따라 개인이 중증근무력증(MG) 치료와 진단을 받을 가능성이 높아지고 있습니다. 또한 의료 전문가들도 중증근무력증(MG)과 그 치료법에 대한 지식이 높아지면서 효율적인 치료법에 대한 요구가 증가하고 있습니다.

중증근무력증(MG)에 대한 인식을 높이고 의료 인프라를 개선하기 위한 정부의 이니셔티브이 시장 성장에 박차를 가하고 있습니다.

중증근무력증(MG) 치료제 시장 - 세분화 분석 :

중증근무력증(MG) 치료제 세계 시장은 약물 유형별, 연령대별, 유통 채널별, 지역별로 구분됩니다.

약물 유형별로는 흉선 절제술, 단일클론항체, 콜린에스테라아제 억제제, 신속면역요법, 만성 면역조절제, 기타 5가지로 분류됩니다. 단클론항체 부문은 중증근무력증(MG) 치료에서 높은 정확도와 효능의 향상으로 인해 가장 높은 시장 점유율을 차지할 것으로 예상됩니다. 단클론항체의 사용은 평생 부신피질 스테로이드에 대한 노출을 줄이고 장기적인 결과를 개선하기 위해 증가하고 있습니다.

시장은 유통 채널에 따라 약국 및 소매 약국, 병원 약국, 온라인 제공업체 등 세 가지로 분류됩니다. 병원 내 약국은 예측 기간 동안 우위를 유지할 것으로 보입니다. 이 부문은 고급 장비에 대한 높은 수요와 병원의 MG 치료를 위한 대규모 환자 풀에 대한 접근성으로 인해 이 부문에 속합니다. 또한, 이러한 시설에서 다양한 치료 옵션을 사용할 수 있기 때문에 치료 및 진단을 위한 환자 방문이 증가하고 있습니다. 첨단 의료 인프라에 대한 투자 증가도 큰 비중을 차지하는 주요 요인입니다.

중증근무력증(MG) 치료제 시장 - 지리적 통찰력

지리적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양 및 중동 및 아프리카으로 분석됩니다. 이 지역은 비즈니스를 가져 오는 국가에 따라 더 세분화됩니다. 중증 근무력증(MG) 치료제 시장 점유율은 북미가 가장 높습니다. 자가 면역 질환 평가의 성장, 혁신적인 의약품을 제공하는 주요 기업의 존재, 중증 근무력증(MG)의 높은 발생률, 개선된 의료 인프라에 대한 접근성 등이 중증 근무력증(MG) 치료 산업을 견인할 것으로 예상됩니다. 또한, 아시아태평양은 자가면역질환 및 가용한 치료 옵션에 대한 인식 제고 캠페인 증가, 자가면역질환 증가, 중증근무력증(MG)의 효과적인 치료 옵션 개발을 위한 투자 증가로 인해 괄목할 만한 성장세를 보일 것으로 예상됩니다. 또한, 신흥국의 의료비 지출 급증은 시장 확대에 유리한 기회를 제공하여 중증근무력증(MG) 치료 시장을 견인할 것으로 예상됩니다.

중증근무력증(MG) 치료제 시장 - 경쟁상황:

정부와 같은 일부 조직은 자가면역 질환에 대해 개인에게 상담을 제공하고 있으며, 전통적인 구매 방식에 비해 온라인 쇼핑을 선호하는 소비자가 증가함에 따라 전자상거래는 세계 대기업과 중소기업에 필수적인 도구가 되고 있습니다. 또한, 의약품 사용법과 중증근무력증(MG)에 대해 사람들을 교육하는 건강 앱을 통한 여러 애니메이션이 중증근무력증(MG) 치료 시장의 성장에 기여하고 있습니다. 또한, 주요 시장 기업은 중증 근무력증(MG) 치료 산업의 제품 포트폴리오를 강화하기 위해 전략적 제휴, 인수, 제품 승인, 확장 및 합의를 주요 개발 전략으로 채택하고 있습니다. 예를 들어, 2021년 3월, 세계 사람들의 건강과 복지를 개선하는 세계 의료 기업 Grifols는 광범위한 면역글로불린을 생산하는 새로운 방법을 촉진하기 위해 GigaGen Inc.를 인수한다고 발표했습니다.

목차

제1장 중증근무력증(MG) 치료 시장 개요

  • 조사 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 내역
  • 경쟁 인사이트

제3장 중증근무력증(MG) 치료 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 향후 시장 동향

제4장 중증근무력증(MG) 치료 산업 조사

  • PEST 분석
  • Porter의 Five Forces 분석
  • 성장 전망 매핑
  • 규제 구조 분석

제5장 중증근무력증(MG) 치료 시장 : COVID-19의 영향 분석

  • COVID-19 이전의 영향 분석
  • COVID-19 이후의 영향 분석

제6장 중증근무력증(MG) 치료 시장 구도

  • 중증근무력증(MG) 치료 시장 점유율 분석, 2022년
  • 주요 제조업체별 분석 데이터
    • 기존 기업 분석
    • 신규 기업 분석

제7장 중증근무력증(MG) 치료 시장 : 약제 클래스별

  • 개요
    • 약제 클래스별 부문 점유율 분석
    • 흉선 절제술
    • 단클론항체
    • 코린에스테라제 억제제
    • 신속 면역치료
    • 만성 면역 조절제
    • 기타

제8장 중증근무력증(MG) 치료 시장 : 연령층별

  • 개요
    • 연령층별 부문 점유율 분석
    • 55세 미만
    • 55세 이상

제9장 중증근무력증(MG) 치료 시장 : 유통 채널별

  • 개요
    • 판매채널별 부문 점유율 분석
    • 드럭스토어·소매 약국
    • 병원 약국
    • 온라인 공급업체

제10장 중증근무력증(MG) 치료 시장 : 지역별

  • 서론
  • 북미
    • 개요
    • 북미 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제11장 주요 벤더 분석 : 중증근무력증(MG) 치료 산업

  • 경쟁 대시보드
  • 기업 개요
    • F.Hoffmann-La Roche AG
    • Alexion Pharmaceutical Inc.
    • Zydus Lifesciences Limited
    • Grifols SA
    • Shire plc
    • Kedrion
    • Avadel Pharmaceuticals, Plc.
    • Octapharma AG
    • Novartis
    • Bausch Health Companies Inc.
    • Pfizer, Inc.
    • AbbVie Inc.
    • GlaxoSmithKline Plc.

제12장 애널리스트 전방위 전망

LSH 23.12.14

REPORT HIGHLIGHT

Myasthenia gravis treatment market size was valued at USD 2,012.43 Million in 2022, expanding at a CAGR of 9.4% from 2023 to 2030.

Myasthenia gravis (MG) is a type of chronic, rare, and progressive neuromuscular disorder that causes weakness of the head, eye, limb, spinal, and respiratory muscles. Antibodies against the acetylcholine receptor (AchR) that prevent proper electrical signal transmission from nerves to muscles are produced in these autoimmune disorders. Additionally, facial paralysis, drooping of eyelids, double vision, and difficulty in walking are symptoms of myasthenia gravis. These diseases are diagnosed by numerous tests including blood tests for antibodies, Magnetic Resonance Imaging (MRI), edrophonium test, repetitive nerve stimulation test, and Computed Tomography (CT).

Myasthenia Gravis Treatment Market- Market Dynamics

Rising prevalence and increasing awareness about myasthenia gravis worldwide driving the market growth

The rising global incidence of myasthenia gravis, the adoption of innovative treatments for myasthenia gravis, and increased knowledge about early diagnosis are the primary drivers driving the development of the myasthenia gravis treatment market. Moreover, the growing focus of pharmaceutical companies on the development of novel drugs for disease treatment is witnessing significant growth in the myasthenia gravis treatment market. Additionally, various medications, including immunosuppressants and monoclonal antibodies, are being tested and developed for their efficacy in treating myasthenia gravis. However, side effects associated with the drugs used for treating myasthenia gravis are expected to restrain the market growth shortly. Furthermore, rising awareness about myasthenia gravis among healthcare professionals and patients is majorly contributing to the increase in demand for effective treatments. In line with this, individuals are more likely to seek treatment and diagnosis for myasthenia gravis as more people become aware of its signs and risks. Healthcare professionals are also becoming more knowledgeable about the disease and its available treatments, leading to an increased demand for efficient treatments.

Myasthenia Gravis Treatment Market- Key Insights

  • As per the analysis shared by our research analyst, the global myasthenia gravis treatment market is estimated to grow annually at a CAGR of around 9.4% over the forecast period (2023-2030)
  • The myasthenia gravis treatment industry is projected to grow at a significant rate due to the rising awareness about myasthenia gravis among healthcare professionals and patients
  • Based on drug class segmentation, monoclonal antibodies was predicted to show maximum market share in the year 2022
  • Based on distribution channel segmentation, hospital pharmacies was the leading type in 2022

Government initiatives to increase consciousness regarding myasthenia gravis and improve healthcare infrastructure are fueling the market growth.

Myasthenia Gravis Treatment Market- Segmentation Analysis:

The global myasthenia gravis treatment market is segmented on the basis of drug class, age group, distribution channel, and region.

The market is divided into five categories based on drug class: thymectomy, monoclonal antibodies, cholinesterase inhibitors, rapid immunotherapies, chronic immunomodulators, and others. The monoclonal antibodies segment is expected to hold the highest market share due to the high precision in treating myasthenia gravis and improved efficacy. The rising use of monoclonal antibodies aims to reduce lifelong exposure to corticosteroids and improve long-term results.

The market is divided into three categories based on distribution channels: drugstore and retail pharmacies, hospital pharmacies, and online providers. The hospital pharmacies segment is likely to maintain its dominance over the forecast period. The segment is attributed to access to the high demand for advanced equipment and a large patient pool for MG treatment in hospital settings. Additionally, the availability of a broad range of treatment options in such facilities has increased patient visits for treatment and diagnosis. The rising investment in state-of-the-art healthcare infrastructures is the prime factor contributing to its large share.

Myasthenia Gravis Treatment Market- Geographical Insights

Geographically, this market is analyzed into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further segmented as per the nations bringing business. North America has the biggest market share for myasthenia gravis therapy. The growth in autoimmune disease evaluation, the existence of significant companies providing innovative medicines, the high incidence of myasthenia gravis, and the accessibility of improved healthcare infrastructure are all expected to drive the myasthenia gravis treatment industry. Moreover, Asia-Pacific is accounted to witness notable growth due to the increase in awareness campaigns regarding autoimmune diseases & available treatment options, rising number of autoimmune diseases, and rising investments for the development of effective treatment options for myasthenia gravis. In addition, in emerging economies upsurge in healthcare expenditure is anticipated to provide lucrative opportunities for market expansion, driving the myasthenia gravis treatment market.

Myasthenia Gravis Treatment Market- Competitive Landscape:

Several organizations such as the government are counseling individuals regarding autoimmune diseases. E-commerce has become a vital tool for large and small businesses across the globe, due to the increase in the preference of consumers for online shopping as compared to traditional purchasing methods. Additionally, several animations through health apps to educate people regarding the usage of medications and myasthenia gravis have contributed toward the myasthenia gravis treatment market growth. Moreover, major market players have adopted strategic alliance, acquisition, product approval, expansion, and agreement as key developmental strategies to enhance the product portfolio of the myasthenia gravis treatment industry. For instance, in March 2021, Grifols a global healthcare company to improve the health and well-being of people worldwide announced to acquire GigaGen Inc. to boost a novel method to generate a broad range of immunoglobulins.

Recent Developments:

For instance, in April 2023, CSL Behring, a global biotechnology company, has received FDA approval for a 50mL/10gm prefilled syringe for Hizentra. CSL Behring offers a comprehensive variety of prefilled syringe sizes to satisfy the specific needs of persons suffering from Primary Immunodeficiency as well as Chronic Inflammatory Demyelinating Polyneuropathy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET KEY PLAYERS

  • F.Hoffmann-La Roche AG
  • Alexion Pharmaceutical Inc.
  • Zydus Lifesciences Limited
  • Grifols SA
  • Shire plc
  • Kedrion
  • Avadel Pharmaceuticals, Plc.
  • Octapharma AG
  • Novartis
  • Bausch Health Companies Inc.
  • Pfizer, Inc.
  • AbbVie Inc.
  • GlaxoSmithKline Plc.

GLOBALMYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS

  • Thymectomy
  • Monoclonal Antibodies
  • Cholinesterase Inhibitors
  • Rapid Immunotherapies
  • Chronic Immunomodulators
  • Others

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP

  • Below 55 years
  • Above 55 years

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • Drug store and retail pharmacies
  • Hospital pharmacies
  • Online providers

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Myasthenia Gravis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Myasthenia Gravis Treatment Market Snippet by Drug Class
    • 2.1.2. Myasthenia Gravis Treatment Market Snippet by Age Group
    • 2.1.3. Myasthenia Gravis Treatment Market Snippet by Distribution Channel
    • 2.1.4. Myasthenia Gravis Treatment Market Snippet by Country
    • 2.1.5. Myasthenia Gravis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Myasthenia Gravis Treatment Key Market Trends

  • 3.1. Myasthenia Gravis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Myasthenia Gravis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Myasthenia Gravis Treatment Market Opportunities
  • 3.4. Myasthenia Gravis Treatment Market Future Trends

4. Myasthenia Gravis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Myasthenia Gravis Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Myasthenia Gravis Treatment Market Landscape

  • 6.1. Myasthenia Gravis Treatment Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Myasthenia Gravis Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022&2030 (%)
    • 7.1.2. Thymectomy
    • 7.1.3. Monoclonal Antibodies
    • 7.1.4. Cholinesterase Inhibitors
    • 7.1.5. Rapid Immunotherapies
    • 7.1.6. Chronic Immunomodulators
    • 7.1.7. Others

8. Myasthenia Gravis Treatment Market - By Age Group

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Age Group, 2022&2030 (%)
    • 8.1.2. Below 55 years
    • 8.1.3. Above 55 years

9. Myasthenia Gravis Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022&2030 (%)
    • 9.1.2. Drug store and retail pharmacies
    • 9.1.3. Hospital pharmacies
    • 9.1.4. Online providers

10. Myasthenia Gravis Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022&2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Myasthenia Gravis Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Myasthenia Gravis Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Myasthenia Gravis Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Myasthenia Gravis Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Myasthenia Gravis Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Myasthenia Gravis Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. F.Hoffmann-La Roche AG
    • 11.2.2. Alexion Pharmaceutical Inc.
    • 11.2.3. Zydus Lifesciences Limited
    • 11.2.4. Grifols SA
    • 11.2.5. Shire plc
    • 11.2.6. Kedrion
    • 11.2.7. Avadel Pharmaceuticals, Plc.
    • 11.2.8. Octapharma AG
    • 11.2.9. Novartis
    • 11.2.10. Bausch Health Companies Inc.
    • 11.2.11. Pfizer, Inc.
    • 11.2.12. AbbVie Inc.
    • 11.2.13. GlaxoSmithKline Plc.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제